Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study

BACKGROUND: Detecting pre-clinical bladder cancer (BC) using urinary biomarkers may provide a valuable opportunity for screening and management. Telomerase reverse transcriptase (TERT) promoter mutations detectable in urine have emerged as promising BC biomarkers. METHODS: We performed a nested case...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosen, Md Ismail, Sheikh, Mahdi, Zvereva, Maria, Scelo, Ghislaine, Forey, Nathalie, Durand, Geoffroy, Voegele, Catherine, Poustchi, Hossein, Khoshnia, Masoud, Roshandel, Gholamreza, Sotoudeh, Masoud, Nikmanesh, Arash, Etemadi, Arash, Avogbe, Patrice Hodonou, Chopard, Priscilia, Delhomme, Tiffany Myriam, Foll, Matthieu, Manel, Arnaud, Vian, Emmanuel, Weiderpass, Elisabete, Kamangar, Farin, Boffetta, Paolo, Pharaoh, Paul D., Dawsey, Sanford M., Abnet, Christian C., Brennan, Paul, McKay, James, Malekzadeh, Reza, Calvez-Kelm, Florence Le
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118568/
https://www.ncbi.nlm.nih.gov/pubmed/32081602
http://dx.doi.org/10.1016/j.ebiom.2020.102643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118568/
https://www.ncbi.nlm.nih.gov/pubmed/32081602
http://dx.doi.org/10.1016/j.ebiom.2020.102643

Ejemplares similares